<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24587" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Follicular Lymphoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kaseb</surname>
            <given-names>Hatem</given-names>
          </name>
          <aff>Cleveland Clinic</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ali</surname>
            <given-names>Muhammad Ashar</given-names>
          </name>
          <aff>Saint Clare's Denville Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gasalberti</surname>
            <given-names>David P.</given-names>
          </name>
          <aff>Inspira Health Network</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Koshy</surname>
            <given-names>Nebu V.</given-names>
          </name>
          <aff>Louisiana State University HSC</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hatem Kaseb declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Ashar Ali declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>David Gasalberti declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nebu Koshy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24587.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Follicular lymphoma (FL) is the second most&#x000a0;prevalent type of non-Hodgkin lymphoma, accounting for up to 30% of all lymphomas. It is generally an indolent B-cell lymphoproliferative disorder graded from 1 to 3 (low- to high-grade manifestations) based on histology. This activity reviews the classification and pathophysiology of&#x000a0;FL, focusing on its&#x000a0;slow growth and prolonged survival. Learners will&#x000a0;gain insights into optimizing management strategies&#x000a0;and explore advancements in treatment modalities to enhance patient outcomes. The role of the interprofessional team is also covered, emphasizing&#x000a0;collaborative approaches for comprehensive patient care.&#x000a0;</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the broad spectrum of clinical manifestations in follicular lymphoma (FL), which include diverse presentations across various stages and grades.</p></list-item><list-item><p>Implement&#x000a0;the diagnostic process involved in examining patients suspected of having FL.</p></list-item><list-item><p>Select appropriate pharmacologic treatments for FL tailored to the disease grade and individual patient needs.&#x000a0;</p></list-item><list-item><p>Communicate&#x000a0;the importance of improving care coordination among interprofessional team members to improve outcomes for patients affected by FL.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24587&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24587">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24587.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Follicular lymphoma (FL) is the second most common type of non-Hodgkin lymphoma (NHL), accounting for almost 30% of all lymphomas, and the most common subtype of clinically&#x000a0;indolent NHL. FL is a slow-growing B-cell lymphoproliferative disorder, with survival calculated in years. Based on histology, FL is graded from 1&#x000a0;to 3 (low grade to high grade).<xref ref-type="bibr" rid="article-24587.r1">[1]</xref><xref ref-type="bibr" rid="article-24587.r2">[2]</xref></p>
      </sec>
      <sec id="article-24587.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>FL originates from germinal&#x000a0;or follicular center B-cells. Most cases of FL show at the translocation (14;18)(q32;q21), which leads to an overexpression of B-cell lymphoma 2 (BCL2), an antiapoptotic protein. About 5% of FLs have BCL-6&#x02013;deregulating mutations. BCL-6 is required for germinal center formation. BCL-6&#x02013;related protein is a repressor of transcription and modulates the interleukin-4 (IL-4) response of B-cells.<xref ref-type="bibr" rid="article-24587.r3">[3]</xref>&#x000a0;</p>
        <p>Other upregulated genes thought to play a role in&#x000a0;FL are associated with <italic toggle="yes">p21</italic>, <italic toggle="yes">p16</italic>, and <italic toggle="yes">G1</italic> arrest. Similarly, regulatory proteins (p120, p16, CKD10, p21), transcription factors (inhibitor of DNA-binding 2 [Id2] and paired box 5 [PAX5]), and cell-cell interaction&#x02013;related genes (tumor necrosis factor <italic toggle="yes">[TNF]</italic>, IL-4 receptor&#x000a0;&#x003b1; <italic toggle="yes">[IL4RA],</italic> and IL-2 receptor subunit gamma <italic toggle="yes">[IL2RG]</italic>) are also upregulated. Adhesion-related genes, such as myeloid-related&#x000a0;protein<italic toggle="yes">&#x000a0;(</italic><italic toggle="yes">MRP)14</italic> and <italic toggle="yes">MRP8,</italic> are downregulated in FL.<xref ref-type="bibr" rid="article-24587.r4">[4]</xref></p>
      </sec>
      <sec id="article-24587.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>FL is the second most common form of NHL in the US, with an estimated incidence of 6 new cases&#x000a0;per 100,000 persons&#x000a0;per year.<xref ref-type="bibr" rid="article-24587.r5">[5]</xref>&#x000a0;The rate of FL is higher in Caucasians than&#x000a0;in Asians and African Americans.</p>
        <p>FL is typically found&#x000a0;in the US and Europe but less so in the rest of the world.&#x000a0;It is a disease of older adults (median age 55 years) and relatively uncommon in children; rarely is FL diagnosed in patients under 20 years of age. Exposure to pesticides and herbicides has been established as a risk factor.<xref ref-type="bibr" rid="article-24587.r2">[2]</xref></p>
      </sec>
      <sec id="article-24587.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Morphological assessment of a lymph node excisional biopsy is crucial for diagnosing FL. Lymph nodes will show variable-sized, closely packed follicles containing small cleaved cells without nucleoli (centrocytes) and larger noncleaved cells with moderate cytoplasm, open chromatin, and multiple nucleoli (centroblasts). The morphology will also show minimal apoptotic cells or tingible body macrophages. The mantle zones are typically absent, and necrosis is rare. Usually, there is interfollicular involvement or capsular infiltration. Different patterns include diffuse, floral, and incipient.</p>
        <p>There are 4 FL variants:</p>
        <list list-type="order">
          <list-item>
            <p>In situ follicular neoplasia (formerly called FL in situ)</p>
          </list-item>
          <list-item>
            <p>Duodenal-type FL</p>
          </list-item>
          <list-item>
            <p>Testicular FL&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Diffuse variant of FL</p>
          </list-item>
        </list>
        <p>In 2017, the World Health Organization (WHO) Classification of Lymphoid Neoplasms&#x000a0;distinguished pediatric FL from FL, categorizing pediatric FL as&#x000a0;an independent entity.<xref ref-type="bibr" rid="article-24587.r2">[2]</xref><xref ref-type="bibr" rid="article-24587.r6">[6]</xref></p>
        <p>FL typically involves the paratrabecular areas of the bone marrow. Centroblasts are enlarged, rapidly dividing B-cells in a lymphoid follicle. Per WHO Classification, the grading of FL is based on&#x000a0;the percentage of centroblasts.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Grade 1:</bold>&#x000a0;Follicular small cleaved cell lymphoma; 0 to 5 centroblasts&#x000a0;per&#x000a0;high power field (HPF)</p>
          </list-item>
          <list-item>
            <p><bold>Grade 2:</bold>&#x000a0;Follicular mixed-cell lymphoma; 6&#x000a0;to 15 centroblasts per HPF</p>
          </list-item>
          <list-item>
            <p><bold>Grade 3:</bold>&#x000a0;Follicular large cell lymphoma; more than 15 centroblasts&#x000a0;per HPF
<list list-type="bullet"><list-item><p><bold>Grade 3A:</bold> Centrocytes present</p></list-item><list-item><p><bold>Grade 3B:</bold> Solid&#x000a0;sheets of centroblasts</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>It is clinically important to differentiate grades 1&#x000a0;and 2&#x000a0;from grade 3. If areas of diffuse large B-cell lymphoma exist with FL, the exact percentage of diffuse large B-cell lymphoma (DLBCL) should be reported. Immunohistochemistry (IHC) is useful in confirming the FL diagnosis. Positive stains supporting FL include clusters of differentiation (CD)10, CD19, CD20 (strong), CD79a, BCL2 within follicles, and BCL6. Variable stains include CD30, CD11c, CD23, CD25, CD43 and surface immunoglobulin. Negative stains include T-cell markers such as CD5 (although mixed T-cells are often present) and cyclin D1.<xref ref-type="bibr" rid="article-24587.r2">[2]</xref><xref ref-type="bibr" rid="article-24587.r6">[6]</xref><xref ref-type="bibr" rid="article-24587.r7">[7]</xref></p>
      </sec>
      <sec id="article-24587.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>FL&#x000a0;typically presents with generalized painless lymphadenopathy, which is waxing and waning in nature. FL commonly involves axillary, cervical, femoral, and inguinal lymph nodes; rarely, it may present with an asymptomatic large mediastinal mass. Only 20% of patients with FL experience B symptoms (night sweats, fever, weight loss). Increased serum lactate<italic toggle="yes">&#x000a0;</italic>dehydrogenase (LDH) is also seen in 20% of the patients. Usually, FL only involves bone marrow and lymphoid organs.<xref ref-type="bibr" rid="article-24587.r8">[8]</xref><xref ref-type="bibr" rid="article-24587.r9">[9]</xref>&#x000a0;In children, FL majorly affects lymphoid tissues (tonsils and lymph nodes) of the head and neck.<xref ref-type="bibr" rid="article-24587.r2">[2]</xref></p>
        <p>The disease is usually indolent with a favorable prognosis. Marrow involvement occurs in most cases (&#x0003e;50%), with&#x000a0;the paratrabecular pattern of infiltration being the most common. In some cases, lymphocytosis with atypical forms shows&#x000a0;deeply cleft nuclei. Spleen infiltration presents as lymphocyte aggregates in the white pulp.</p>
        <p>There are some subtypes of FL, such as double-hit follicular lymphoma (myelocytomatosis<italic toggle="yes"> [</italic><italic toggle="yes">MYC]</italic> and <italic toggle="yes">BCL2</italic> translocations) and low-grade FL with a high proliferation index, that present with low-grade morphology and a relatively aggressive course; more research on these and other rare subtypes is underway.<xref ref-type="bibr" rid="article-24587.r10">[10]</xref><xref ref-type="bibr" rid="article-24587.r11">[11]</xref>&#x000a0;</p>
        <p>Transformation of FL to different aggressive forms of NHL, such as DLBCL, Burkitt and Burkitt-like lymphoma,&#x000a0;high-grade B-cell lymphoma (not otherwise specified or with double-&#x000a0;or triple-hit genetics), and B-cell acute lymphoblastic leukemia (B-ALL) occurs and is associated with an unfavorable outcome. Transformation of FL can be suspected clinically when there are rapidly enlarging disproportionate masses, B symptoms, and abnormal laboratory tests (such as elevated serum LDH or calcium).<xref ref-type="bibr" rid="article-24587.r1">[1]</xref><xref ref-type="bibr" rid="article-24587.r2">[2]</xref><xref ref-type="bibr" rid="article-24587.r5">[5]</xref></p>
      </sec>
      <sec id="article-24587.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Evaluation of FL should include history, physical examination, laboratory studies (complete blood count with differential, routine chemistries, and LDH), and imaging (including CT, MRI, and whole-body combined fluorodeoxyglucose positron emission tomography with computed tomography [FDG PET/CT]). Diagnosis of FL usually requires a lymph node morphological assessment and flow cytometry; sometimes, genetic testing is incorporated to confirm the diagnosis.</p>
        <p>Peripheral blood smear rarely shows atypical lymphocytes that have scant cytoplasm and deeply cleaved nucleus <xref ref-type="bibr" rid="article-24587.r12">[12]</xref>. Effacement of nodal architecture with CD20+ CD10+ BCL2+ cells (small- to medium-sized cells) supports FL diagnosis. In some cases, it is hard to differentiate FL from reactive hyperplasia. For these cases, the assessment of CD10 will be helpful since the expression of the stain supports FL. Bone marrow biopsy should be performed before the initiation of therapy to confirm staging.</p>
        <p>Genetics is a useful tool for assessing FL as most cases will show clonally rearranged immunoglobulin genes. Further, most cases will show at translocation (14;18)(q32;q21).&#x000a0;The translocation affects the immunoglobulin heavy chain <italic toggle="yes">(IgH)</italic> and <italic toggle="yes">BCL2</italic>&#x000a0;and leads to an overexpression of <italic toggle="yes">BCL2</italic>, which prevents cells in the follicular center from undergoing apoptosis. <italic toggle="yes">BCL2</italic> is sensitive but not specific for FL and can be present in other forms of NHL, such as DLBCL <xref ref-type="bibr" rid="article-24587.r13">[13]</xref>. After the achievement of remission, follow-up of patients should be planned every&#x000a0;3 months during the first year and then every&#x000a0;3 to&#x000a0;6 months <xref ref-type="bibr" rid="article-24587.r1">[1]</xref>.</p>
      </sec>
      <sec id="article-24587.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The management of FL depends on the disease stage. Options available for the treatment of&#x000a0;FL include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Radiotherapy (RT)</p>
          </list-item>
          <list-item>
            <p>Immunochemotherapy (rituximab plus chemotherapy)</p>
          </list-item>
          <list-item>
            <p>Bundamustine with immunotherapy</p>
          </list-item>
          <list-item>
            <p>Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)</p>
          </list-item>
          <list-item>
            <p>Immunochemotherapy plus RT</p>
          </list-item>
          <list-item>
            <p>Cyclophosphamide, vincristine, and prednisolone (CVP)</p>
          </list-item>
          <list-item>
            <p>Single-agent rituximab</p>
          </list-item>
          <list-item>
            <p>Observation until progression</p>
          </list-item>
        </list>
        <p>The choice of regimen depends on the disease stage, the physician's preference, and the patient's preference. In stage&#x000a0;I lymphomas,&#x000a0;RT is preferred in grades 1, 2, and 3A. In contrast, patients with grade 3B FL are treated with aggressive regimens such as R-CHOP&#x000a0;that are used for other aggressive lymphomas (eg, DLBCL).</p>
        <p>Treatment of stage II, III, and IV FL mainly focuses on improving quality of life, alleviation of symptoms, and reversing cytopenias. Asymptomatic patients are mainly observed closely without any intervention. Anti-CD20 antibodies (obinutuzumab, rituximab) are combined with chemotherapy regimens for the treatment of symptomatic advanced FLs.</p>
        <p>Autologous hematopoietic stem cell transplantation is the preferred management for recurrent/relapsed patients or patients who have undergone a transformation to higher-grade lymphoma. Patients with advanced, relapsed, or refractory disease are encouraged to participate in clinical trials of new therapies like chimeric antigen receptor (CAR) T-cell therapy).<xref ref-type="bibr" rid="article-24587.r1">[1]</xref><xref ref-type="bibr" rid="article-24587.r13">[13]</xref><xref ref-type="bibr" rid="article-24587.r14">[14]</xref></p>
      </sec>
      <sec id="article-24587.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>FL&#x000a0;is differentiated from other types of lymphomas based on nodular pattern, absence of tangible body macrophages, monoclonal cells, and immunophenotyping (ie, CD10, BCL-2, BCL-6). The differential diagnosis of FL include:<xref ref-type="bibr" rid="article-24587.r15">[15]</xref><xref ref-type="bibr" rid="article-24587.r16">[16]</xref><xref ref-type="bibr" rid="article-24587.r17">[17]</xref><xref ref-type="bibr" rid="article-24587.r18">[18]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Follicular colonization by other low-grade lymphomas</p>
          </list-item>
          <list-item>
            <p>Mantle cell lymphoma with a diffuse pattern</p>
          </list-item>
          <list-item>
            <p>Marginal zone B-cell lymphoma</p>
          </list-item>
          <list-item>
            <p>Peripheral T-cell lymphoma</p>
          </list-item>
          <list-item>
            <p>Reactive hyperplasia</p>
          </list-item>
          <list-item>
            <p>Small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24587.s10" sec-type="Radiation Oncology">
        <title>Radiation Oncology</title>
        <p>RT&#x000a0;continues to play a critical role in the treatment of FL. In low-grade (grades 1, 2, and indolent 3A) stage I and contiguous stage II disease, it may be considered the sole curative treatment modality.<xref ref-type="bibr" rid="article-24587.r19">[19]</xref>&#x000a0;In more advanced cases, palliative&#x000a0;RT is utilized to alleviate pain or prevent impending end-organ damage. Despite declining utilization in the setting of lymphomas, a large&#x000a0;National Cancer Database (NCDB) retrospective analysis suggests that the use of RT in treating early-stage&#x000a0;FL is associated with improved overall survival at 5- and 10-year follow-up on multivariate analysis.<xref ref-type="bibr" rid="article-24587.r20">[20]</xref></p>
        <p>
<bold>Simulation</bold>
</p>
        <p>The use of the&#x000a0;immobilization technique is dependent on the area to be treated. For example, involvement of the head and neck region would require a thermoplastic mask mold.<xref ref-type="bibr" rid="article-24587.r21">[21]</xref>&#x000a0;Motion management is encouraged for tumors of the thoracic cavity or close to the diaphragm.<xref ref-type="bibr" rid="article-24587.r21">[21]</xref>&#x000a0;Once appropriate immobilization is completed, a 3- to 5-mm slice CT scan of the region of interest is performed. A contrast-enhanced CT is ideal for better anatomic delineation of the tumor versus the vasculature.<xref ref-type="bibr" rid="article-24587.r21">[21]</xref>&#x000a0;However, this may not be possible in many departments. Functional imaging with FDG-PET is strongly encouraged.</p>
        <p>
<bold>Treatment Delivery&#x000a0;</bold>
</p>
        <p>Three-dimensional conformal treatment delivery is most commonly utilized. However, other techniques such as&#x000a0;intensity-modulated radiation therapy (IMRT) or even proton therapy may be considered in patients who fail to meet initial dose constraints, re-irradiation cases, or younger patients where normal tissue sparing is critical.&#x000a0;</p>
        <p>
<bold>Target Delineation</bold>
</p>
        <p>Involved site&#x000a0;RT (ISRT) is the dominant conceptual framework for target delineation in lymphoma. It assumes chemotherapy eliminates microscopic regional disease and, as a result, treats a significantly smaller volume than its predecessor, involved field&#x000a0;RT (IFRT).</p>
        <p>Prechemotherapy functional imaging with FDG-PET imaging is critical as it helps determine the extent of the disease and the response to treatment. A prechemotherapy gross target volume (GTV) should be outlined first using the PET as a guide. The postchemotherapy GTV should also be outlined.</p>
        <p>Ideally, the clinical target volume (CTV) should encompass both the pre- and postchemotherapy GTV, but should be excluded from normal structures such as the lung, heart, great vessels, etc.<xref ref-type="bibr" rid="article-24587.r21">[21]</xref><xref ref-type="bibr" rid="article-24587.r22">[22]</xref>&#x000a0;However, modifications are necessary in the context of early-stage&#x000a0;FL since these patients are not being treated with chemotherapy. Therefore, the CTV is typically much more generous and encompasses uninvolved adjacent nodal groups within the nodal compartment.<xref ref-type="bibr" rid="article-24587.r21">[21]</xref><xref ref-type="bibr" rid="article-24587.r22">[22]</xref></p>
        <p>An internal target volume (ITV) may be needed, especially to account for motion. The planning target volume (PTV) is an expansion of the CTV, taking into account daily set-up uncertainty, which is a function of treatment location and immobilization technique.<xref ref-type="bibr" rid="article-24587.r22">[22]</xref><bold>&#x000a0;</bold>If the involved nodes are more than 5 cm apart, they may be treated with separate fields.<xref ref-type="bibr" rid="article-24587.r22">[22]</xref>&#x000a0;</p>
        <p>
<bold>Dosing&#x000a0;</bold>
</p>
        <p>In the definitive setting, early-stage low-grade FLs can be treated&#x000a0;at a dose of 24&#x000a0;to 30 Gy in 1.5&#x000a0;to 2.0 Gy/fraction. Dose de-escalation trials suggest equivalent local failure, progression-free survival, and overall survival in patients with indolent NHL receiving 24 Gy versus 40&#x000a0;to 45 Gy.<xref ref-type="bibr" rid="article-24587.r23">[23]</xref>&#x000a0;More recently, more dramatic dose de-escalation trials have been attempted.</p>
        <p>The Follicular Radiotherapy&#x000a0;Trial (FoRT), a noninferiority trial, compared 4 Gy in 2 fractions to 24 Gy in 12 fractions for follicular and marginal zone lymphomas.<xref ref-type="bibr" rid="article-24587.r24">[24]</xref>&#x000a0;The findings suggest inferior 5-year progression-free survival in the 4-Gy arm (70% vs 90%).<xref ref-type="bibr" rid="article-24587.r24">[24]</xref>&#x000a0;However, the authors imply that 4 Gy in 2 fractions ("Boom-Boom") may be an effective palliative regimen, which is accepted in the National Comprehensive Cancer Network (NCCN) guidelines.<xref ref-type="bibr" rid="article-24587.r24">[24]</xref></p>
        <table-wrap id="article-24587.table0" position="float" orientation="portrait">
          <caption>
            <title>Table. Commonly accepted dose and volume constraints</title>
          </caption>
          <table style="width: 294.009px; border-color: black;" border="yes" cellpadding="5">
            <tbody>
              <tr style="height: 35px;">
                <td style="height: 35px; width: 41px;" rowspan="1" colspan="1">
<p><bold>Organ </bold></p>
</td>
                <td style="height: 35px; width: 67px;" rowspan="1" colspan="1">
<p><bold>Optimal</bold></p>
</td>
                <td style="height: 35px; width: 27.0089px;" rowspan="1" colspan="1">
<p><bold>Variation Acceptable</bold></p>
</td>
              </tr>
              <tr style="height: 83px;">
                <td style="height: 83px; width: 41px;" rowspan="1" colspan="1">
<p>Heart</p>
</td>
                <td style="height: 83px; width: 67px;" rowspan="1" colspan="1">
<p>Mean: &#x0003c;5 Gy</p>
<p>V15: &#x0003c;10%</p>
<p>V30:&#x000a0;</p>
</td>
                <td style="height: 83px; width: 27.0089px;" rowspan="1" colspan="1">
<p>Mean:</p>
<p>V15: &#x0003c;25%</p>
<p>V30: &#x0003c;15%</p>
</td>
              </tr>
              <tr style="height: 83px;">
                <td style="height: 83px; width: 41px;" rowspan="1" colspan="1">
<p>Lung</p>
</td>
                <td style="height: 83px; width: 67px;" rowspan="1" colspan="1">
<p>Mean: &#x0003c;8 Gy</p>
<p>V5: &#x0003c;35%</p>
<p>V20: &#x0003c;20%</p>
</td>
                <td style="height: 83px; width: 27.0089px;" rowspan="1" colspan="1">
<p>Mean: &#x0003c;8-12 Gy</p>
<p>V5: &#x0003c;35-45%</p>
<p>V20: &#x0003c;20-28%</p>
</td>
              </tr>
              <tr style="height: 35px;">
                <td style="height: 35px; width: 41px;" rowspan="1" colspan="1">
<p>Thyroid</p>
</td>
                <td style="height: 35px; width: 67px;" rowspan="1" colspan="1">
<p>V25: &#x0003c;62.5%</p>
</td>
                <td style="height: 35px; width: 27.0089px;" rowspan="1" colspan="1">
</td>
              </tr>
              <tr style="height: 83.8572px;">
                <td style="height: 83.8572px; width: 41px;" rowspan="1" colspan="1">
<p>Breast</p>
</td>
                <td style="height: 83.8572px; width: 67px;" rowspan="1" colspan="1">
<p>Mean: &#x0003c;4 Gy</p>
<p>V4: &#x0003c;10%</p>
</td>
                <td style="height: 83.8572px; width: 27.0089px;" rowspan="1" colspan="1">
<p>Mean: &#x0003c;4-15 Gy</p>
<p>V4: &#x0003c;10-20%</p>
<p>V10: &#x0003c;10%</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>Modified from Wirth et al 2020.<xref ref-type="bibr" rid="article-24587.r25">[25]</xref>&#x000a0;</p>
        <p>
<bold>Outcomes&#x000a0;</bold>
</p>
        <p>Long-term outcomes for stage I&#x000a0;and II FLs treated with&#x000a0;RT alone are excellent, with a 97% complete response rate.<xref ref-type="bibr" rid="article-24587.r26">[26]</xref>&#x000a0;Fifteen-year overall survival and progression-free survival for a patient treated with radiotherapy alone are 57% and 46%, respectively.<xref ref-type="bibr" rid="article-24587.r26">[26]</xref>&#x000a0;An NCDB analysis reviewing the management of early-stage&#x000a0;FL showed a 14% improvement in 10-year overall survival (54% vs 68%) in patients who received&#x000a0;RT&#x000a0;with or without chemotherapy versus those who received chemotherapy alone or observation.<xref ref-type="bibr" rid="article-24587.r20">[20]</xref>&#x000a0;Other retrospective reviews have suggested similar improvements in disease-specific survival and overall survival in patients given upfront RT.<xref ref-type="bibr" rid="article-24587.r27">[27]</xref></p>
        <p>PET/CT staged patients with stage I FL appear to have better outcomes than those staged without it. This may suggest that many so-called early-stage patients treated in the pre-PET staging era may have had more extensive disease than previously thought.<xref ref-type="bibr" rid="article-24587.r28">[28]</xref><bold>&#x000a0;</bold></p>
        <p>In the palliative setting, short-course&#x000a0;RT with Boom-Boom has shown a high overall response rate of 88%.<xref ref-type="bibr" rid="article-24587.r29">[29]</xref>&#x000a0;This regimen has several advantages, including a low incidence of toxicity, fewer treatment visits, high response rates, and ease of retreatment in the event of recurring pain/symptoms.&#x000a0;</p>
        <p>
<bold>Relapsed&#x000a0;FL</bold>
</p>
        <p>Approximately 30% of patients who have received definitive radiotherapy for early-stage indolent&#x000a0;FL will relapse within 5 years.<xref ref-type="bibr" rid="article-24587.r30">[30]</xref>&#x000a0;In the vast majority of cases, relapse occurs outside of the previous treatment field.<xref ref-type="bibr" rid="article-24587.r30">[30]</xref>&#x000a0;Local relapse occurs in &#x0003c;10% of cases but may be amenable to re-irradiation with acceptable toxicity.<xref ref-type="bibr" rid="article-24587.r30">[30]</xref><xref ref-type="bibr" rid="article-24587.r31">[31]</xref>&#x000a0;</p>
        <p>
<bold>Toxicity</bold>
</p>
        <p>Late toxicities are the most concerning aspect of RT treatment; their development depends&#x000a0;on the treatment location, field size, and dose. Prior to the widespread use of chemotherapy for lymphoma,&#x000a0;RT was the definitive treatment modality. At that time, the doses were far higher, and treatment fields were more comprehensive using mantle and inverted Y fields. Although these treatments produced long-term survivors, they did so at the cost of several late toxicities, including secondary malignancies, cardiomyopathies, valvulopathies, restrictive pulmonary disease, bowel obstructions, infertility, and endocrine deficiencies.&#x000a0;&#x000a0;</p>
        <p>The introduction of chemotherapy and a concerted effort on the part of radiation oncologists to reduce the field size and dose of radiation has helped to reduce late toxicity. However, these issues persist. In a randomized dose de-escalation trial for indolent lymphomas, the most common late toxicities included xerostomia (13%), telangiectasias (14%), alopecia (9%), bowel toxicity (2%), and bladder toxicity (1%).<xref ref-type="bibr" rid="article-24587.r23">[23]</xref>&#x000a0;</p>
        <p>The risk of secondary malignancies, specifically solid tumors, increases linearly with dose.<xref ref-type="bibr" rid="article-24587.r32">[32]</xref> Radiation is associated with a 1.5- to 15-fold increase in secondary malignancy risk.<xref ref-type="bibr" rid="article-24587.r32">[32]</xref> Cardiovascular complications such as conduction abnormalities, pericardial disease, valvulopathies, and coronary atherosclerosis are possible with treatment directed to the thorax. In a large multivariate analysis, the hazard ratio for radiation was 1.015 per Gy for the development of cardiovascular disease.<xref ref-type="bibr" rid="article-24587.r32">[32]</xref></p>
      </sec>
      <sec id="article-24587.s11" sec-type="Staging">
        <title>Staging</title>
        <p>NHLs&#x000a0;are divided into the following stages:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Stage I:</bold> Single lymph node group or single extra lymphatic organ involved without lymph node involvement</p>
          </list-item>
          <list-item>
            <p><bold>Stage II:</bold> Two or more lymph node regions involved on the same side of the diaphragm with or without the involvement of an extra lymphatic organ</p>
          </list-item>
          <list-item>
            <p><bold>Stage III:</bold> Lymph nodes on both sides of the diaphragm involved</p>
          </list-item>
          <list-item>
            <p><bold>Stage IV:</bold> One or more extra lymphoid organs diffusely involved with or without lymph node involvement&#x000a0;<xref ref-type="bibr" rid="article-24587.r33">[33]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24587.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis and risk assessment of FL&#x000a0;are determined based on the Follicular&#x000a0;Lymphoma&#x000a0;International Prognostic Index (FLIP)2 study risk factors, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Beta 2 microglobulin&#x000a0;greater than the upper limit of normal</p>
          </list-item>
          <list-item>
            <p>Bone marrow involvement</p>
          </list-item>
          <list-item>
            <p>Hemoglobin &#x0003c;12g/dL</p>
          </list-item>
          <list-item>
            <p>The diameter of the largest involved node&#x000a0;greater than 6 cm</p>
          </list-item>
          <list-item>
            <p>Age&#x000a0;over&#x000a0;60 years</p>
          </list-item>
        </list>
        <p>The 5-year progression-free survival based on these risk factors is:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Low risk&#x000a0;</bold>(0 risk factors): 80%</p>
          </list-item>
          <list-item>
            <p><bold>Intermediate risk&#x000a0;</bold>(1-2 risk factors): 51%</p>
          </list-item>
          <list-item>
            <p><bold>High risk&#x000a0;</bold>(3-5 risk factors): 19%<xref ref-type="bibr" rid="article-24587.r1">[1]</xref><xref ref-type="bibr" rid="article-24587.r2">[2]</xref><xref ref-type="bibr" rid="article-24587.r1">[1]</xref><xref ref-type="bibr" rid="article-24587.r34">[34]</xref><xref ref-type="bibr" rid="article-24587.r35">[35]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24587.s13" sec-type="Complications">
        <title>Complications</title>
        <p>FL complications include bone marrow suppression, organ dysfunction, and adverse effects related to high-dose chemotherapy.</p>
      </sec>
      <sec id="article-24587.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should be educated about the prognosis and the possible adverse side effects from the chemotherapeutic regimes and hematopoietic stem cell transplantation before beginning treatment.</p>
      </sec>
      <sec id="article-24587.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <list list-type="bullet">
          <list-item>
            <p>FL is the second most common type of NHL.</p>
          </list-item>
          <list-item>
            <p>FL typically presents with generalized painless lymphadenopathy.</p>
          </list-item>
          <list-item>
            <p>The disease is usually indolent with a favorable prognosis.</p>
          </list-item>
          <list-item>
            <p>Most cases of FL show at translocation (14;18)(q32;q21), which leads to an overexpression of BCL2, an antiapoptotic protein.</p>
          </list-item>
          <list-item>
            <p>The WHO Classification (2017) has a pathological grading system (Grade 1, 2, or 3) for FL that depends on the evaluation of centroblasts.</p>
          </list-item>
          <list-item>
            <p>FL workup should include history, physical examination, and laboratory studies, and imaging.</p>
          </list-item>
          <list-item>
            <p>The management of FL depends on the disease stage.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24587.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>FL is the second most common form of NHL. The prognosis is overall favorable. FL needs an interprofessional management approach with a medical oncologist, pathologist, infectious disease physician, pharmacist, and oncology nurse, all of whom play a role in management. Drug interventions have shown better outcomes than wait-and-watch in the treatment of&#x000a0;FL.<xref ref-type="bibr" rid="article-24587.r36">[36]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-24587.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24587&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24587">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/follicular-lymphoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=24587">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24587/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24587">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-24587.s18">
        <title>References</title>
        <ref id="article-24587.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freedman</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Follicular lymphoma: 2015 update on diagnosis and management.</article-title>
            <source>Am J Hematol</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>90</volume>
            <issue>12</issue>
            <fpage>1171</fpage>
            <page-range>1171-8</page-range>
            <pub-id pub-id-type="pmid">26769125</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swerdlow</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Campo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pileri</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Siebert</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Advani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ghielmini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Salles</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Zelenetz</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>The 2016 revision of the World Health Organization classification of lymphoid neoplasms.</article-title>
            <source>Blood</source>
            <year>2016</year>
            <month>May</month>
            <day>19</day>
            <volume>127</volume>
            <issue>20</issue>
            <fpage>2375</fpage>
            <page-range>2375-90</page-range>
            <pub-id pub-id-type="pmid">26980727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ma</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Risk Factors of Follicular Lymphoma.</article-title>
            <source>Expert Opin Med Diagn</source>
            <year>2012</year>
            <month>Jul</month>
            <day>01</day>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>323</fpage>
            <page-range>323-333</page-range>
            <pub-id pub-id-type="pmid">22754588</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Husson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Carideo</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Neuberg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schultze</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Munoz</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Marks</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Donovan</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Chillemi</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>O'Connell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Freedman</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays.</article-title>
            <source>Blood</source>
            <year>2002</year>
            <month>Jan</month>
            <day>01</day>
            <volume>99</volume>
            <issue>1</issue>
            <fpage>282</fpage>
            <page-range>282-9</page-range>
            <pub-id pub-id-type="pmid">11756183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kridel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sehn</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Gascoyne</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Can histologic transformation of follicular lymphoma be predicted and prevented?</article-title>
            <source>Blood</source>
            <year>2017</year>
            <month>Jul</month>
            <day>20</day>
            <volume>130</volume>
            <issue>3</issue>
            <fpage>258</fpage>
            <page-range>258-266</page-range>
            <pub-id pub-id-type="pmid">28408460</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Weisenburger</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Ruby</surname>
                <given-names>EI</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Vose</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bierman</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Bast</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Daley</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Armitage</surname>
                <given-names>JO</given-names>
              </name>
            </person-group>
            <article-title>Prognostic value of cellular proliferation and histologic grade in follicular lymphoma.</article-title>
            <source>Blood</source>
            <year>1995</year>
            <month>Jun</month>
            <day>15</day>
            <volume>85</volume>
            <issue>12</issue>
            <fpage>3671</fpage>
            <page-range>3671-8</page-range>
            <pub-id pub-id-type="pmid">7780151</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Miyata-Takata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yoshino</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Pathology of follicular lymphoma.</article-title>
            <source>J Clin Exp Hematop</source>
            <year>2014</year>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-9</page-range>
            <pub-id pub-id-type="pmid">24942941</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freedman</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Follicular lymphoma: 2018 update on diagnosis and management.</article-title>
            <source>Am J Hematol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>93</volume>
            <issue>2</issue>
            <fpage>296</fpage>
            <page-range>296-305</page-range>
            <pub-id pub-id-type="pmid">29314206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kridel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sehn</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Gascoyne</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis of follicular lymphoma.</article-title>
            <source>J Clin Invest</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>122</volume>
            <issue>10</issue>
            <fpage>3424</fpage>
            <page-range>3424-31</page-range>
            <pub-id pub-id-type="pmid">23023713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Medeiros</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Double-hit follicular lymphoma with MYC and BCL2 translocations: a study of 7 cases with a review of literature.</article-title>
            <source>Hum Pathol</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>58</volume>
            <fpage>72</fpage>
            <page-range>72-77</page-range>
            <pub-id pub-id-type="pmid">27544800</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hochberg</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Muzikansky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Hasserjian</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Low histologic grade follicular lymphoma with high proliferation index: morphologic and clinical features.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>29</volume>
            <issue>11</issue>
            <fpage>1490</fpage>
            <page-range>1490-6</page-range>
            <pub-id pub-id-type="pmid">16224216</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sarkozy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Baseggio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Feugier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Callet-Bauchu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Karlin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Seymour</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Lebras</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Michallet</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Offner</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dumas</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Traverse-Glehen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ffrench</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lopez-Guillermo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Coiffier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Felman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Salles</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis.</article-title>
            <source>Br J Haematol</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>164</volume>
            <issue>5</issue>
            <fpage>659</fpage>
            <page-range>659-67</page-range>
            <pub-id pub-id-type="pmid">24274024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McNamara</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dyer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoskin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Illidge</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lyttelton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Montoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ramsay</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Ardeshna</surname>
                <given-names>K</given-names>
              </name>
              <collab>Haemato-oncology Task Force of the British Committee for Standards in Haematology (BCSH)</collab>
              <collab>British Society for Haematology Committee</collab>
            </person-group>
            <article-title>Guidelines on the investigation and management of follicular lymphoma.</article-title>
            <source>Br J Haematol</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>156</volume>
            <issue>4</issue>
            <fpage>446</fpage>
            <page-range>446-67</page-range>
            <pub-id pub-id-type="pmid">22211428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dada</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of follicular lymphoma: A comprehensive review.</article-title>
            <source>Eur J Haematol</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>103</volume>
            <issue>3</issue>
            <fpage>152</fpage>
            <page-range>152-163</page-range>
            <pub-id pub-id-type="pmid">31270855</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boyd</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Natkunam</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Warnke</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results.</article-title>
            <source>Appl Immunohistochem Mol Morphol</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>116</fpage>
            <page-range>116-31</page-range>
            <pub-id pub-id-type="pmid">22820658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mittal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Puri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nangia</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sachdeva</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Follicular lymphoma transforming into anaplastic diffuse large B-cell lymphoma of oral cavity: A case report with review of literature.</article-title>
            <source>J Oral Maxillofac Pathol</source>
            <year>2015</year>
            <season>Sep-Dec</season>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>379</fpage>
            <page-range>379-84</page-range>
            <pub-id pub-id-type="pmid">26980969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Guan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ouyang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Development of follicular lymphoma after treatment of diffuse large B-cell lymphoma: two case reports with review of literature.</article-title>
            <source>Int J Clin Exp Pathol</source>
            <year>2018</year>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>324</fpage>
            <page-range>324-332</page-range>
            <pub-id pub-id-type="pmid">31938115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nathwani</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Winberg</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Diamond</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Bearman</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Morphologic criteria for the differentiation of follicular lymphoma from florid reactive follicular hyperplasia: a study of 80 cases.</article-title>
            <source>Cancer</source>
            <year>1981</year>
            <month>Oct</month>
            <day>15</day>
            <volume>48</volume>
            <issue>8</issue>
            <fpage>1794</fpage>
            <page-range>1794-806</page-range>
            <pub-id pub-id-type="pmid">7026023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zelenetz</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Christian</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Abramson</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Advani</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Bartlett</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Budde</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Caimi</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>De Vos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dholaria</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fakhri</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fayad</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Glenn</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Habermann</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Hernandez-Ilizaliturri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hsi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaminski</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Kelsey</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Krivacic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>LaCasce</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Narkhede</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rabinovitch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ramakrishnan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Saeed</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Svoboda</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Swinnen</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Tuscano</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vose</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Dwyer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Sundar</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>NCCN Guidelines&#x000ae; Insights: B-Cell Lymphomas, Version 5.2021.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>19</volume>
            <issue>11</issue>
            <fpage>1218</fpage>
            <page-range>1218-1230</page-range>
            <pub-id pub-id-type="pmid">34781267</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vargo</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Gill</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Balasubramani</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Beriwal</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>What is the optimal management of early-stage low-grade follicular lymphoma in the modern era?</article-title>
            <source>Cancer</source>
            <year>2015</year>
            <month>Sep</month>
            <day>15</day>
            <volume>121</volume>
            <issue>18</issue>
            <fpage>3325</fpage>
            <page-range>3325-34</page-range>
            <pub-id pub-id-type="pmid">26042364</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Illidge</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Specht</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yahalom</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Aleman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Berthelsen</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Constine</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dabaja</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dharmarajan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ricardi</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Wirth</surname>
                <given-names>A</given-names>
              </name>
              <collab>International Lymphoma Radiation Oncology Group</collab>
            </person-group>
            <article-title>Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2014</year>
            <month>May</month>
            <day>01</day>
            <volume>89</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <page-range>49-58</page-range>
            <pub-id pub-id-type="pmid">24725689</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Specht</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yahalom</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Illidge</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Berthelsen</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Constine</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Eich</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Girinsky</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hoppe</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Mauch</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mikhaeel</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>A</given-names>
              </name>
              <collab>ILROG</collab>
            </person-group>
            <article-title>Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG).</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2014</year>
            <month>Jul</month>
            <day>15</day>
            <volume>89</volume>
            <issue>4</issue>
            <fpage>854</fpage>
            <page-range>854-62</page-range>
            <pub-id pub-id-type="pmid">23790512</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lowry</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Qian</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Benstead</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Illidge</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Linch</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jack</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hoskin</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial.</article-title>
            <source>Radiother Oncol</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>100</volume>
            <issue>1</issue>
            <fpage>86</fpage>
            <page-range>86-92</page-range>
            <pub-id pub-id-type="pmid">21664710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoskin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Popova</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schofield</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Brammer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brunt</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Madhavan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Illidge</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gallop-Evans</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Syndikus</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Clifton-Hadley</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kirkwood</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>332</fpage>
            <page-range>332-340</page-range>
            <pub-id pub-id-type="pmid">33539729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wirth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mikhaeel</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Aleman</surname>
                <given-names>BMP</given-names>
              </name>
              <name>
                <surname>Pinnix</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Constine</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Ricardi</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Illidge</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Eich</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Hoppe</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Dabaja</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Kirova</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Berthelsen</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Dieckmann</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yahalom</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Specht</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2020</year>
            <month>Aug</month>
            <day>01</day>
            <volume>107</volume>
            <issue>5</issue>
            <fpage>909</fpage>
            <page-range>909-933</page-range>
            <pub-id pub-id-type="pmid">32272184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barzenje</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Cvancarova Sm&#x000e5;stuen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liest&#x000f8;l</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Foss&#x000e5;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Delabie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kolstad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Holte</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years.</article-title>
            <source>PLoS One</source>
            <year>2015</year>
            <volume>10</volume>
            <issue>7</issue>
            <fpage>e0131158</fpage>
            <pub-id pub-id-type="pmid">26147646</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pugh</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Ballonoff</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Newman</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rabinovitch</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a Surveillance, Epidemiology, and End Results database analysis.</article-title>
            <source>Cancer</source>
            <year>2010</year>
            <month>Aug</month>
            <day>15</day>
            <volume>116</volume>
            <issue>16</issue>
            <fpage>3843</fpage>
            <page-range>3843-51</page-range>
            <pub-id pub-id-type="pmid">20564102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brady</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Binkley</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Hajj</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chelius</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chau</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Balogh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Levis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Filippi</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mac Manus</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wirth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oguchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vistisen</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Andraos</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Aleman</surname>
                <given-names>BMP</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kirova</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hardy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reinartz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Eich</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Bratman</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Constine</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Dabaja</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>El-Galaly</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Hodgson</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Ricardi</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Yahalom</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hoppe</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Mikhaeel</surname>
                <given-names>NG</given-names>
              </name>
            </person-group>
            <article-title>Definitive radiotherapy for localized follicular lymphoma staged by <sup>18</sup>F-FDG PET-CT: a collaborative study by ILROG.</article-title>
            <source>Blood</source>
            <year>2019</year>
            <month>Jan</month>
            <day>17</day>
            <volume>133</volume>
            <issue>3</issue>
            <fpage>237</fpage>
            <page-range>237-245</page-range>
            <pub-id pub-id-type="pmid">30446493</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Fung</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gospodarowicz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hodgson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pintile</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tsang</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Palliation by low-dose local radiation therapy for indolent non-Hodgkin lymphoma.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2011</year>
            <month>Dec</month>
            <day>01</day>
            <volume>81</volume>
            <issue>5</issue>
            <fpage>e781</fpage>
            <page-range>e781-6</page-range>
            <pub-id pub-id-type="pmid">21167657</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Binkley</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Brady</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Hajj</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chelius</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chau</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Balogh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Levis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Filippi</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>MacManus</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wirth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oguchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vistisen</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Andraos</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Aleman</surname>
                <given-names>BMP</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kirova</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Hardy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reinartz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Eich</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Bratman</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Constine</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Dabaja</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>El-Galaly</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Hodgson</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Ricardi</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Yahalom</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mikhaeel</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Hoppe</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2019</year>
            <month>Jul</month>
            <day>01</day>
            <volume>104</volume>
            <issue>3</issue>
            <fpage>522</fpage>
            <page-range>522-529</page-range>
            <pub-id pub-id-type="pmid">30858143</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grignano</surname>
                <given-names>&#x000c9;</given-names>
              </name>
              <name>
                <surname>Deau-Fischer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Loganadane</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Breton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Burroni</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bouscary</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kirova</surname>
                <given-names>YM</given-names>
              </name>
            </person-group>
            <article-title>Radiotherapy of relapse-refractory follicular lymphoma.</article-title>
            <source>Cancer Radiother</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>126</fpage>
            <page-range>126-130</page-range>
            <pub-id pub-id-type="pmid">29477304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Leeuwen</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2016</year>
            <month>Dec</month>
            <day>02</day>
            <volume>2016</volume>
            <issue>1</issue>
            <fpage>323</fpage>
            <page-range>323-330</page-range>
            <pub-id pub-id-type="pmid">27913498</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armitage</surname>
                <given-names>JO</given-names>
              </name>
            </person-group>
            <article-title>Staging non-Hodgkin lymphoma.</article-title>
            <source>CA Cancer J Clin</source>
            <year>2005</year>
            <season>Nov-Dec</season>
            <volume>55</volume>
            <issue>6</issue>
            <fpage>368</fpage>
            <page-range>368-76</page-range>
            <pub-id pub-id-type="pmid">16282281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Solal-C&#x000e9;ligny</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Roy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Colombat</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Armitage</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Arranz-Saez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Au</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Bellei</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brice</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Caballero</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Coiffier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Conde-Garcia</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Doyen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Federico</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Garcia-Conde</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Guglielmi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hagenbeek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ha&#x000ef;oun</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>LeBlanc</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lister</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Lopez-Guillermo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Milpied</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Morel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mounier</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Proctor</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Rohatiner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Soubeyran</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tilly</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Vitolo</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Zinzani</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Zucca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Montserrat</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Follicular lymphoma international prognostic index.</article-title>
            <source>Blood</source>
            <year>2004</year>
            <month>Sep</month>
            <day>01</day>
            <volume>104</volume>
            <issue>5</issue>
            <fpage>1258</fpage>
            <page-range>1258-65</page-range>
            <pub-id pub-id-type="pmid">15126323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Relander</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Farinha</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Connors</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Sehn</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Gascoyne</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Prognostic factors in follicular lymphoma.</article-title>
            <source>J Clin Oncol</source>
            <year>2010</year>
            <month>Jun</month>
            <day>10</day>
            <volume>28</volume>
            <issue>17</issue>
            <fpage>2902</fpage>
            <page-range>2902-13</page-range>
            <pub-id pub-id-type="pmid">20385990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24587.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ardeshna</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Qian</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Braganca</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lowry</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Patrick</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Warden</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pocock</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Miall</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jack</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stephens</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Walewski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ferhanoglu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bradstock</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Linch</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>424</fpage>
            <page-range>424-35</page-range>
            <pub-id pub-id-type="pmid">24602760</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
